{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:23:01Z","timestamp":1793726581176,"version":"4.6.1"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.phrs.2021.105924","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T06:11:11Z","timestamp":1633155071000},"page":"105924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Renin angiotensin aldosterone system in pulmonary fibrosis: Pathogenesis to therapeutic possibilities"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-7143","authenticated-orcid":false,"given":"Dipankar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2718-7544","authenticated-orcid":false,"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Mandloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-6170","authenticated-orcid":false,"given":"Vinayak","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2021.105924_bib1","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1172\/JCI139519","article-title":"Contributions of alveolar epithelial cell quality control to pulmonary fibrosis","volume":"130","author":"Katzen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2021.105924_bib2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2021.105924_bib3","doi-asserted-by":"crossref","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012;366:1968\u20131977. doi:10.1056\/NEJMoa1113354.","DOI":"10.1056\/NEJMoa1113354"},{"key":"10.1016\/j.phrs.2021.105924_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201411-2044ED","article-title":"Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions","volume":"191","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.phrs.2021.105924_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/875910","article-title":"Angiotensinogen gene transcription in pulmonary fibrosis","volume":"2012","author":"Uhal","year":"2012","journal-title":"Int J. Pept."},{"issue":"16","key":"10.1016\/j.phrs.2021.105924_bib6","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.3390\/ijms21165663","article-title":"Metabolic dysregulation in idiopathic pulmonary fibrosis","volume":"21","author":"Bargagli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2021.105924_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1183\/09031936.00130310","article-title":"Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis","volume":"39","author":"Montes","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2021.105924_bib8","doi-asserted-by":"crossref","first-page":"15561","DOI":"10.1038\/srep15561","article-title":"Chronic activation of the renin-angiotensin system induces lung fibrosis","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105924_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00408-019-00278-5","article-title":"Evaluation of renin and soluble (Pro)renin receptor in patients with IPF. a comparison with hypersensitivity pneumonitis","volume":"197","author":"Eduardo","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.phrs.2021.105924_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1164\/ajrccm\/141.1.117","article-title":"Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases","volume":"141","author":"Specks","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.phrs.2021.105924_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.biocel.2011.11.019","article-title":"Angiotensin signalling in pulmonary fibrosis","volume":"44","author":"Uhal","year":"2012","journal-title":"Int J. Biochem Cell Biol."},{"key":"10.1016\/j.phrs.2021.105924_bib12","first-page":"L885","article-title":"Angiotensin II induces apoptosis in human and rat alveolar epithelial cells","volume":"276","author":"Wang","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib13","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3892\/etm.2017.4429","article-title":"Regulation of the angiotensin II-p22phox-reactive oxygen species signaling pathway, apoptosis and 8-oxoguanine-DNA glycosylase 1 retrieval in hyperoxia-induced lung injury and fibrosis in rats","volume":"13","author":"Wang","year":"2017","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.phrs.2021.105924_bib14","doi-asserted-by":"crossref","first-page":"L887","DOI":"10.1152\/ajplung.00432.2005","article-title":"Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis","volume":"291","author":"Li","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","article-title":"Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105924_bib16","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1038\/s41598-017-03474-6","article-title":"Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system","volume":"7","author":"Shi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105924_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00210-016-1253-3","article-title":"Aliskiren attenuates bleomycin-induced pulmonary fibrosis in rats: focus on oxidative stress, advanced glycation end products, and matrix metalloproteinase-9","volume":"389","author":"Abuelezz","year":"2016","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib18","doi-asserted-by":"crossref","first-page":"L143","DOI":"10.1152\/ajplung.2000.279.1.L143","article-title":"Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor","volume":"279","author":"Wang","year":"2000","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000090140","article-title":"Losartan attenuates bleomycin-induced pulmonary fibrosis in rats","volume":"73","author":"Yao","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.phrs.2021.105924_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081090","article-title":"Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments","volume":"8","author":"Ji","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105924_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00408-012-9410-z","article-title":"Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project","volume":"190","author":"Couluris","year":"2012","journal-title":"Lung"},{"key":"10.1016\/j.phrs.2021.105924_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.chest.2019.04.015","article-title":"Association of angiotensin modulators with the course of idiopathic pulmonary fibrosis","volume":"156","author":"Kreuter","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2021.105924_bib23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1513\/AnnalsATS.201903-198RL","article-title":"Angiotensin receptor blockers and subclinical interstitial lung disease: the MESA study","volume":"16","author":"Gannon","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.phrs.2021.105924_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2021.105924_bib25","doi-asserted-by":"crossref","first-page":"10035","DOI":"10.1038\/srep10035","article-title":"Atlas of tissue renin-angiotensin-aldosterone system in human: a transcriptomic meta-analysis","volume":"5","author":"Nehme","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105924_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.667254","article-title":"The role of renin-angiotensin-aldosterone system in the heart and lung: focus on COVID-19","volume":"12","author":"Mascolo","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/1381612033455431","article-title":"The pulmonary renin-angiotensin system","volume":"9","author":"Marshall","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.105924_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s004180000235","article-title":"Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease","volume":"115","author":"Bullock","year":"2001","journal-title":"Histochem Cell Biol."},{"key":"10.1016\/j.phrs.2021.105924_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jss.2013.06.052","article-title":"Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury","volume":"185","author":"Chen","year":"2013","journal-title":"J. Surg. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/cjpp-2020-0662","article-title":"Alamandine via MrgD receptor attenuates pulmonary fibrosis via NOX4 and autophagy pathway","volume":"99","author":"Liu","year":"2021","journal-title":"Can. J. Physiol. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension","volume":"186","author":"de Man","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.phrs.2021.105924_bib33","first-page":"5","article-title":"The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis","author":"Abdul-Hafez","year":"2018","journal-title":"JLPRR"},{"key":"10.1016\/j.phrs.2021.105924_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s13054-017-1917-5","article-title":"The evolving role of the renin-angiotensin system in ARDS","volume":"21","author":"Vrigkou","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2021.105924_bib35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2021.105924_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","article-title":"AT2 receptors in cardiovascular and renal diseases","volume":"125","author":"Kaschina","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.phrs.2021.105924_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105924_bib40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105924_bib41","doi-asserted-by":"crossref","first-page":"L341","DOI":"10.1152\/ajplung.00360.2012","article-title":"Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury","volume":"305","author":"Wagenaar","year":"2013","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bph.12318","article-title":"AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma","volume":"170","author":"Rodrigues-Machado","year":"2013","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111365","article-title":"Mas receptor activation attenuates allergic airway inflammation via inhibiting JNK\/CCL2-induced macrophage recruitment","volume":"137","author":"Hong","year":"2021","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.regpep.2012.05.093","article-title":"Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction","volume":"177","author":"Mur\u00e7a","year":"2012","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2021.105924_bib45","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/bph.13946","article-title":"Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes","volume":"174","author":"Goru","year":"2017","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105223","article-title":"Activation of angiotensin II type-2 receptor protects against cigarette smoke-induced COPD","volume":"161","author":"Mei","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib47","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.120.11941","article-title":"Angiotensin II type 2 receptor: A target for protection against hypertension, metabolic dysfunction, and organ remodeling","volume":"77","author":"Fatima","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13280","article-title":"Anti-fibrotic mechanisms of angiotensin AT2 -receptor stimulation","volume":"227","author":"Sumners","year":"2019","journal-title":"Acta Physiol. (Oxf.)"},{"key":"10.1016\/j.phrs.2021.105924_bib49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1381612826666200115092015","article-title":"Emerging role of angiotensin AT2 receptor in anti-inflammation: an update","volume":"26","author":"Patel","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.105924_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/BSR20171301","article-title":"Potential contribution of alveolar epithelial type I cells to pulmonary fibrosis","volume":"37","author":"Kasper","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.phrs.2021.105924_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.200810-1615OC","article-title":"Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis","volume":"181","author":"Sisson","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.phrs.2021.105924_bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-4652(200011)185:2<253::AID-JCP10>3.0.CO;2-#","article-title":"Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo","volume":"185","author":"Wang","year":"2000","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib53","doi-asserted-by":"crossref","first-page":"L501","DOI":"10.1152\/ajplung.00273.2002","article-title":"Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo","volume":"284","author":"Li","year":"2003","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1742-7843.2007.00006.x","article-title":"Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1","volume":"100","author":"Uhal","year":"2007","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"10.1016\/j.phrs.2021.105924_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-019-1232-6","article-title":"Vitamin D deficiency exacerbates bleomycin-induced pulmonary fibrosis partially through aggravating TGF-\u03b2\/Smad2\/3-mediated epithelial-mesenchymal transition","volume":"20","author":"Li","year":"2019","journal-title":"Respir. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib56","first-page":"3171","article-title":"Vitamin D and pulmonary fibrosis: a review of molecular mechanisms","volume":"12","author":"Ma","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.phrs.2021.105924_bib57","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1164\/ajrccm.161.6.9907004","article-title":"Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor","volume":"161","author":"Marshall","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2021.105924_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40139-013-0017-8","article-title":"Regulation and relevance of myofibroblast responses in idiopathic pulmonary fibrosis","volume":"1","author":"Moore","year":"2013","journal-title":"Curr. Pathobiol. Rep."},{"key":"10.1016\/j.phrs.2021.105924_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13069-015-0023-z","article-title":"Modulation of angiotensin II signaling in the prevention of fibrosis","volume":"8","author":"Murphy","year":"2015","journal-title":"Fibrogenes. Tissue Repair"},{"key":"10.1016\/j.phrs.2021.105924_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.29245\/2689-999X\/2019\/2.1149","article-title":"Epithelial-mesenchymal transition contributes to pulmonary fibrosis via aberrant epithelial\/fibroblastic cross-talk","volume":"3","author":"Hill","year":"2019","journal-title":"J. Lung Health Dis."},{"key":"10.1016\/j.phrs.2021.105924_bib61","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2174\/138161207780618885","article-title":"Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages","volume":"13","author":"Uhal","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.105924_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ijms19082460","article-title":"TGF-\u03b2 signaling in lung health and disease","volume":"19","author":"Saito","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105924_bib63","doi-asserted-by":"crossref","first-page":"L156","DOI":"10.1152\/ajplung.00313.2002","article-title":"Angiotensin II and the fibroproliferative response to acute lung injury","volume":"286","author":"Marshall","year":"2004","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib64","doi-asserted-by":"crossref","first-page":"L790","DOI":"10.1152\/ajplung.00099.2007","article-title":"TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways","volume":"293","author":"Martin","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib65","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1096\/fj.08-114611","article-title":"JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts","volume":"23","author":"Abdul-Hafez","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2021.105924_bib66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1465-9921-5-24","article-title":"Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts","volume":"5","author":"Renzoni","year":"2004","journal-title":"Respir. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib67","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.bbadis.2012.11.021","article-title":"Oxidative stress and pulmonary fibrosis","volume":"1832","author":"Cheresh","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2021.105924_bib68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/ars.2007.1897","article-title":"The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis","volume":"10","author":"Bringardner","year":"2008","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.phrs.2021.105924_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12931-018-0754-7","article-title":"Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review","volume":"19","author":"Fois","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.phrs.2021.105924_bib70","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2012.4604","article-title":"Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease","volume":"19","author":"Dikalov","year":"2013","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.phrs.2021.105924_bib71","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2021.105924_bib72","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/HYPERTENSIONAHA.120.15595","article-title":"ACE2 (Angiotensin-Converting Enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2","volume":"76","author":"Sharma","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib73","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib74","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-020-03015-0","article-title":"Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients","volume":"24","author":"Wu","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2021.105924_bib75","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2021.105924_bib76","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1055\/s-0040-1713678","article-title":"Pathological role of angiotensin II in severe COVID-19","volume":"4","author":"Miesbach","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.phrs.2021.105924_bib77","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2017.09.024","article-title":"A test in context: D-Dimer","volume":"70","author":"Weitz","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105924_bib78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fpubh.2020.00432","article-title":"D-Dimer concentrations and COVID-19 severity: a systematic review and meta-analysis","volume":"8","author":"Paliogiannis","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.phrs.2021.105924_bib79","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/CIRCRESAHA.113.301271","article-title":"The discovery of the ACE2 gene","volume":"112","author":"Marian","year":"2013","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib80","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/SHK.0000000000000633","article-title":"Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease","volume":"46","author":"Jia","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.phrs.2021.105924_bib81","doi-asserted-by":"crossref","first-page":"L178","DOI":"10.1152\/ajplung.00009.2008","article-title":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis","volume":"295","author":"Li","year":"2008","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib82","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00109-012-0859-2","article-title":"Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury","volume":"90","author":"Rey-Parra","year":"2012","journal-title":"J. Mol. Med"},{"key":"10.1016\/j.phrs.2021.105924_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2162","article-title":"The emerging role of ACE2 in physiology and disease","volume":"212","author":"Hamming","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.phrs.2021.105924_bib84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fphys.2018.00271","article-title":"rhACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling","volume":"9","author":"Rathinasabapathy","year":"2018","journal-title":"Front Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib85","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1159\/000430131","article-title":"Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice","volume":"36","author":"Wang","year":"2015","journal-title":"Cell Physiol. Biochem"},{"key":"10.1016\/j.phrs.2021.105924_bib86","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1159\/000374025","article-title":"Angiotensin-converting enzyme 2 inhibits apoptosis of pulmonary endothelial cells during acute lung injury through suppressing SMAD2 phosphorylation","volume":"35","author":"Ji","year":"2015","journal-title":"Cell Physiol. Biochem"},{"key":"10.1016\/j.phrs.2021.105924_bib87","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S252351","article-title":"ACE2 attenuates epithelial-mesenchymal transition in MLE-12 cells induced by silica","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2021.105924_bib88","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1164\/rccm.200912-1840OC","article-title":"The angiotensin-converting enzyme 2\/angiogenesis-(1-7)\/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension","volume":"182","author":"Shenoy","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.phrs.2021.105924_bib89","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1164\/rccm.200811-1678OC","article-title":"Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension","volume":"179","author":"Ferreira","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.phrs.2021.105924_bib90","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.111.00202","article-title":"Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic efficacy","volume":"61","author":"Chen","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib91","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1164\/rccm.201205-0880OC","article-title":"Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models","volume":"187","author":"Shenoy","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.phrs.2021.105924_bib92","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2021.105924_bib93","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105924_bib94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1183\/23120541.00848-2020","article-title":"Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients","volume":"7","author":"van Lier","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.phrs.2021.105924_bib95","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1165\/rcmb.2017-0284OC","article-title":"Angiotensin-(1-7) attenuated cigarette smoking-related pulmonary fibrosis via Improving the Impaired autophagy caused by nicotinamide adenine dinucleotide phosphate reduced oxidase 4-dependent reactive oxygen species","volume":"59","author":"Pan","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105924_bib96","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-\u03baB pathway","volume":"50","author":"Meng","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105924_bib97","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/ars.2013.5818","article-title":"The angiotensin-converting enzyme 2\/angiotensin (1-7)\/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA\/Rho kinase pathway","volume":"22","author":"Meng","year":"2015","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.phrs.2021.105924_bib98","doi-asserted-by":"crossref","first-page":"L269","DOI":"10.1152\/ajplung.00222.2010","article-title":"Regulation of alveolar epithelial cell survival by the ACE-2\/angiotensin 1-7\/Mas axis","volume":"301","author":"Uhal","year":"2011","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109193","article-title":"Exogenous angiotensin (1-7) directly inhibits epithelial-mesenchymal transformation induced by transforming growth factor-\u03b21 in alveolar epithelial cells","volume":"117","author":"Shao","year":"2019","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-0115(00)00138-5","article-title":"Angiotensin-(1-7): an update","volume":"91","author":"Santos","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2021.105924_bib101","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2021.105924_bib102","doi-asserted-by":"crossref","first-page":"L1141","DOI":"10.1152\/ajplung.00029.2016","article-title":"Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice","volume":"311","author":"Magalh\u00e3es","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1183\/13993003.00921-2020","article-title":"Oestrogen-mediated upregulation of the Mas receptor contributes to sex differences in acute lung injury and lung vascular barrier regulation","volume":"57","author":"Erfinanda","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2021.105924_bib104","doi-asserted-by":"crossref","first-page":"L240","DOI":"10.1152\/ajplung.00187.2015","article-title":"Angiotensin-(1-7)\/mas inhibits apoptosis in alveolar epithelial cells through upregulation of MAP kinase phosphatase-2","volume":"310","author":"Gopallawa","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170384","article-title":"Impact of angiotensin II type 1 and G-protein-coupled Mas receptor expression on the pulmonary performance of patients with idiopathic pulmonary fibrosis","volume":"133","author":"Raupp","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2021.105924_bib106","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fphar.2017.00564","article-title":"Anti-fibrotic potential of AT2 receptor agonists","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib107","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1161\/01.CIR.0000072763.98069.B4","article-title":"Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice","volume":"107","author":"Adachi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105924_bib108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1113\/expphysiol.2011.060673","article-title":"Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury","volume":"97","author":"Qi","year":"2012","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib109","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fphys.2018.00180","article-title":"The selective angiotensin II Type 2 receptor agonist, compound 21, attenuates the progression of lung fibrosis and pulmonary hypertension in an experimental model of bleomycin-Induced lung injury","volume":"9","author":"Rathinasabapathy","year":"2018","journal-title":"Front Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib110","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/bph.13044","article-title":"Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis","volume":"172","author":"Bruce","year":"2015","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib111","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/JIR.S160573","article-title":"Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury","volume":"11","author":"Menk","year":"2018","journal-title":"J. Inflamm. Res"},{"key":"10.1016\/j.phrs.2021.105924_bib112","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jmv.25785","article-title":"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19","volume":"92","author":"Cheng","year":"2020","journal-title":"J. Med Virol."},{"key":"10.1016\/j.phrs.2021.105924_bib113","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/256294","article-title":"Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease","volume":"2012","author":"Tikellis","year":"2012","journal-title":"Int J. Pept."},{"key":"10.1016\/j.phrs.2021.105924_bib114","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2021.105924_bib116","unstructured":"VUMC to lead national study to treat severe COVID complications | VUMC Reporter | Vanderbilt University n.d. \u3008https:\/\/news.vumc.org\/2021\/05\/06\/vumc-to-lead-national-study-to-treat-severe-covid-complications\/\u3009 (accessed August 14, 2021)."},{"key":"10.1016\/j.phrs.2021.105924_bib117","unstructured":"COVID-19 med APN01 selected to be tested in ACTIV study - European Biotechnology n.d. \u3008https:\/\/european-biotechnology.com\/up-to-date\/latest-news\/news\/covid-19-med-apn01-selected-to-be-tested-in-activ-study.html\u3009 (accessed September 19, 2021)."},{"key":"10.1016\/j.phrs.2021.105924_bib118","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105924_bib119","doi-asserted-by":"crossref","first-page":"C279","DOI":"10.1152\/ajpcell.00478.2020","article-title":"Soluble ACE2 as a potential therapy for COVID-19","volume":"320","author":"Krishnamurthy","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.phrs.2021.105924_bib120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/HYPERTENSIONAHA.117.10406","article-title":"Angiotensin-(1-7) and vascular function: the clinical context","volume":"71","author":"Touyz","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib121","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.peptides.2007.08.011","article-title":"Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies","volume":"28","author":"Lula","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2021.105924_bib122","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","article-title":"An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats","volume":"57","author":"Marques","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib123","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.108.146431","article-title":"Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog","volume":"328","author":"Kluskens","year":"2009","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.phrs.2021.105924_bib124","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/536426","article-title":"The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction","volume":"2012","author":"Durik","year":"2012","journal-title":"Int J. Hypertens."},{"key":"10.1016\/j.phrs.2021.105924_bib125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2003.12.010","article-title":"Site-specific microinjection of liposomes into the brain for local infusion of a short-lived peptide","volume":"95","author":"Silva-Barcellos","year":"2004","journal-title":"J. Control Release"},{"key":"10.1016\/j.phrs.2021.105924_bib126","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-0716-1472-3_3","article-title":"Engineering chloroplasts for high-level constitutive or inducible transgene expression","volume":"2317","author":"Bock","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105924_bib127","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/HYPERTENSIONAHA.114.03871","article-title":"Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension","volume":"64","author":"Shenoy","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib128","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/mt.2014.179","article-title":"Oral delivery of ACE2\/Ang-(1-7) bioencapsulated in plant cells protects against experimental uveitis and autoimmune uveoretinitis","volume":"22","author":"Shil","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2021.105924_bib129","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents","volume":"51","author":"Hern\u00e1ndez Prada","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2021.105924_bib131","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omtn.2017.04.006","article-title":"Translation of angiotensin-converting enzyme 2 upon liver- and lung-targeted delivery of optimized chemically modified mRNA","volume":"7","author":"Schrom","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2021.105924_bib132","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.HYP.0000037979.53963.8F","article-title":"AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium","volume":"40","author":"Wiemer","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib133","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/fcp.12599","article-title":"Comparison of the effects of losartan, captopril, angiotensin II type 2 receptor agonist compound 21, and MAS receptor agonist AVE 0991 on myocardial ischemia-reperfusion necrosis in rats","volume":"35","author":"Ozhan","year":"2020","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib134","doi-asserted-by":"crossref","first-page":"34643","DOI":"10.1074\/jbc.M805181200","article-title":"Discovery and validation of novel peptide agonists for G-protein-coupled receptors","volume":"283","author":"Shemesh","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105924_bib135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/HYPERTENSIONAHA.110.152942","article-title":"Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor","volume":"56","author":"Savergnini","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105924_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057757","article-title":"The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats","volume":"8","author":"Savergnini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105924_bib137","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/biomedicines9050492","article-title":"20-hydroxyecdysone, from plant extracts to clinical use: therapeutic potential for the treatment of neuromuscular, cardio-metabolic and respiratory diseases","volume":"9","author":"Dinan","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2021.105924_bib138","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13063-020-04998-5","article-title":"Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Dioh","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.phrs.2021.105924_bib139","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17476348.2020.1679628","article-title":"The potential of mesenchymal stem cell therapy for chronic lung disease","volume":"14","author":"Cruz","year":"2020","journal-title":"Expert Rev. Respir. Med"},{"key":"10.1016\/j.phrs.2021.105924_bib140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3727\/096368914X685087","article-title":"Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury","volume":"24","author":"He","year":"2015","journal-title":"Cell Transpl."},{"key":"10.1016\/j.phrs.2021.105924_bib141","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/01902148.2014.938200","article-title":"Mesenchymal stem cell-based angiotensin-converting enzyme 2 in treatment of acute lung injury rat induced by bleomycin","volume":"40","author":"Gao","year":"2014","journal-title":"Exp. Lung Res"},{"key":"10.1016\/j.phrs.2021.105924_bib142","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cbf.3092","article-title":"Combination therapy with human umbilical cord mesenchymal stem cells and angiotensin-converting enzyme 2 is superior for the treatment of acute lung ischemia-reperfusion injury in rats","volume":"33","author":"Zhang","year":"2015","journal-title":"Cell Biochem Funct."},{"key":"10.1016\/j.phrs.2021.105924_bib143","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tice.2015.05.001","article-title":"Biochemical and histological impact of direct renin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced pulmonary fibrosis in adult mice","volume":"47","author":"Asker","year":"2015","journal-title":"Tissue Cell"},{"key":"10.1016\/j.phrs.2021.105924_bib144","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms17071098","article-title":"Angiotensin a\/alamandine\/mrgd axis: another clue to understanding cardiovascular pathophysiology","volume":"17","author":"Hrenak","year":"2016","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105924_bib145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmed.2019.00107","article-title":"Alamandine and its receptor MrgD pair up to join the protective arm of the renin-angiotensin system","volume":"6","author":"Schleifenbaum","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.phrs.2021.105924_bib146","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9975315","article-title":"Assessment of alamandine in pulmonary fibrosis and respiratory mechanics in rodents","volume":"2021","author":"Fernandes","year":"2021","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.phrs.2021.105924_bib147","doi-asserted-by":"crossref","first-page":"210","DOI":"10.29328\/journal.jccm.1001070","article-title":"The renin-angiotensin system: alamandine is reduced in patients with Iihic pulmonary fibrosis","volume":"4","author":"Ta\u00eds Salvi","year":"2019","journal-title":"J. Cardiol. Cardiovasc Med"},{"key":"10.1016\/j.phrs.2021.105924_bib148","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejphar.2013.08.019","article-title":"Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models","volume":"718","author":"Lieber","year":"2013","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105924_bib149","doi-asserted-by":"crossref","first-page":"15","DOI":"10.25011\/cim.v39i1.26326","article-title":"Reduction of acute lung injury by administration of spironolactone after intestinal ischemia and reperfusion in rats","volume":"39","author":"Barut","year":"2016","journal-title":"CIM"},{"key":"10.1016\/j.phrs.2021.105924_bib150","first-page":"501","article-title":"The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats","volume":"51","author":"Atalay","year":"2010","journal-title":"Singap. Med J."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:42:33Z","timestamp":1762353753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821005089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":150,"alternative-id":["S1043661821005089"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105924","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin angiotensin aldosterone system in pulmonary fibrosis: Pathogenesis to therapeutic possibilities","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105924"}}